Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 238

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 238
---
 | $ |   264,351 |   |     | $ |  227,258 |   |

During the three months ended September 30, 2024 and 2023, the Company capitalized website development-related costs of $ 3,299and $ 12,283, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60degreespharma.com ($ 25,374and $ 52,178for the nine months ended September 30, 2024 and 2023, respectively). Amortization expenses for the three months ended September 30, 2024 and 2023 were in the amounts of $ 10,325and $ 7,414, respectively ($ 28,004and $ 20,606for the nine months ended September 30, 2024 and 2023, respectively). During the three months ended September 30, 2024 and 2023, there were write-downs for expired or obsolete patents of $ 2,922and $ 0, respectively ($ 11,300and $ 0for the nine months ended September 30, 2024 and 2023, respectively).

The following table summarizes the estimated future amortization expense for our patents and website development costs as of September 30, 2024:

| Period                        |     | Patents |        |     | Website     
 Development 
 Costs       |        |
|:------------------------------|:----|:--------|-------:|:----|:------------|-------:|
| 2024 (remaining three months) |     | $       |  1,753 |     | $           |  8,718 |
| 2025                          |     |         |  7,010 |     |             | 31,761 |
| 2026                          |     |         |  7,010 |     |             | 12,432 |
| 2027                          |     |         |  7,010 |     |             |  3,094 |
| 2028                          |     |         |  7,010 |     |             |      - |
| Thereafter                    |     |         | 51,106 |     |             |      - |
| Total                         |     | $       | 80,899 |     | $           | 56,005 |

The Company has recorded $ 128,722in capitalized patent expenses that will become amort